Immuron Ltd

AU:IMC Australia Biotechnology
Market Cap
$5.81 Million
AU$9.38 Million AUD
Market Cap Rank
#31469 Global
#980 in Australia
Share Price
AU$0.03
Change (1 day)
-6.45%
52-Week Range
AU$0.03 - AU$0.09
All Time High
AU$0.86
Categories
Companies in Australia Biotechnology
About

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal d… Read more

Immuron Ltd (IMC) - Net Assets

Latest net assets as of June 2025: AU$8.07 Million AUD

Based on the latest financial reports, Immuron Ltd (IMC) has net assets worth AU$8.07 Million AUD as of June 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$10.13 Million) and total liabilities (AU$2.06 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets AU$8.07 Million
% of Total Assets 79.66%
Annual Growth Rate 2.42%
5-Year Change -68.84%
10-Year Change 63.32%
Growth Volatility 919.67

Immuron Ltd - Net Assets Trend (2000–2025)

This chart illustrates how Immuron Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Immuron Ltd (2000–2025)

The table below shows the annual net assets of Immuron Ltd from 2000 to 2025.

Year Net Assets Change
2025-06-30 AU$8.07 Million -36.51%
2024-06-30 AU$12.71 Million -35.21%
2023-06-30 AU$19.62 Million -15.36%
2022-06-30 AU$23.18 Million -10.49%
2021-06-30 AU$25.90 Million +358.81%
2020-06-30 AU$5.64 Million -23.22%
2019-06-30 AU$7.35 Million -12.89%
2018-06-30 AU$8.44 Million +28.36%
2017-06-30 AU$6.57 Million +33.08%
2016-06-30 AU$4.94 Million +2.70%
2015-06-30 AU$4.81 Million -29.12%
2014-06-30 AU$6.79 Million +4581.10%
2013-06-30 AU$144.99K -92.93%
2012-06-30 AU$2.05 Million +18.33%
2011-06-30 AU$1.73 Million -48.49%
2010-06-30 AU$3.36 Million +1919.26%
2009-06-30 AU$-184.87K -116.65%
2008-06-30 AU$1.11 Million -44.05%
2007-06-30 AU$1.98 Million -62.12%
2006-06-30 AU$5.24 Million -24.77%
2005-06-30 AU$6.96 Million +70.75%
2004-06-30 AU$4.08 Million -19.15%
2003-06-30 AU$5.04 Million -20.23%
2002-06-30 AU$6.32 Million -15.41%
2001-06-30 AU$7.48 Million +68.28%
2000-06-30 AU$4.44 Million --

Equity Component Analysis

This analysis shows how different components contribute to Immuron Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 8244320500.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component Amount Percentage
Common Stock AU$88.87 Million 1101.40%
Other Comprehensive Income AU$1.64 Million 20.32%
Total Equity AU$8.07 Million 100.00%

Immuron Ltd Competitors by Market Cap

The table below lists competitors of Immuron Ltd ranked by their market capitalization.

Company Market Cap
Ozaurum Resources Ltd
AU:OZM
 		$4.76 Million
TZ Ltd
AU:TZL
 		$4.76 Million
BRITANNIA LIFE SCIENCES
F:L020
 		$4.76 Million
Gulf Resources, Inc. (NV) Common Stock
NASDAQ:GURE
 		$4.76 Million
Photozou Holdings Inc
PINK:PTZH
 		$4.75 Million
Bakken Water Transfer Services Inc
PINK:BWTX
 		$4.75 Million
Colabor Group Inc
PINK:COLFF
 		$4.75 Million
Ackroo Inc
PINK:AKRFF
 		$4.75 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Immuron Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 12,709,444 to 8,069,055, a change of -4,640,389 (-36.5%).
  • Net loss of 5,215,987 reduced equity.
  • Share repurchases of 396,830 reduced equity.
  • New share issuances of 396,827 increased equity.
  • Other comprehensive income decreased equity by 1,534,293.
  • Other factors increased equity by 2,109,894.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income AU$-5.22 Million -64.64%
Share Repurchases AU$396.83K -4.92%
Share Issuances AU$396.83K +4.92%
Other Comprehensive Income AU$-1.53 Million -19.01%
Other Changes AU$2.11 Million +26.15%
Total Change AU$- -36.51%

Book Value vs Market Value Analysis

This analysis compares Immuron Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.83x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has increased from 0.02x to 0.83x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2000-06-30 AU$1.85 AU$0.03 x
2001-06-30 AU$2.73 AU$0.03 x
2002-06-30 AU$2.15 AU$0.03 x
2003-06-30 AU$1.72 AU$0.03 x
2004-06-30 AU$1.38 AU$0.03 x
2005-06-30 AU$2.10 AU$0.03 x
2006-06-30 AU$1.55 AU$0.03 x
2007-06-30 AU$0.54 AU$0.03 x
2008-06-30 AU$0.29 AU$0.03 x
2009-06-30 AU$-0.04 AU$0.03 x
2010-06-30 AU$0.35 AU$0.03 x
2011-06-30 AU$0.15 AU$0.03 x
2012-06-30 AU$0.17 AU$0.03 x
2013-06-30 AU$0.01 AU$0.03 x
2014-06-30 AU$0.16 AU$0.03 x
2015-06-30 AU$0.06 AU$0.03 x
2016-06-30 AU$0.06 AU$0.03 x
2017-06-30 AU$0.06 AU$0.03 x
2018-06-30 AU$0.06 AU$0.03 x
2019-06-30 AU$0.05 AU$0.03 x
2020-06-30 AU$0.03 AU$0.03 x
2021-06-30 AU$0.12 AU$0.03 x
2022-06-30 AU$0.10 AU$0.03 x
2023-06-30 AU$0.09 AU$0.03 x
2024-06-30 AU$0.06 AU$0.03 x
2025-06-30 AU$0.03 AU$0.03 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Immuron Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -64.64%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -71.58%
  • • Asset Turnover: 0.72x
  • • Equity Multiplier: 1.26x
  • Recent ROE (-64.64%) is above the historical average (-168.00%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2001 -20.89% -318.19% 0.06x 1.05x AU$-2.30 Million
2002 -27.63% -85.74% 0.30x 1.07x AU$-2.31 Million
2004 -28.83% -31.60% 0.75x 1.22x AU$-1.57 Million
2005 -19.21% -27.39% 0.60x 1.16x AU$-2.03 Million
2006 -68.74% -88.95% 0.60x 1.28x AU$-4.08 Million
2007 -170.86% -77.22% 1.29x 1.72x AU$-3.47 Million
2008 -262.88% -975.86% 0.15x 1.75x AU$-2.97 Million
2009 0.00% -442.24% 1.06x 0.00x AU$-2.30 Million
2010 -56.66% -412.61% 0.12x 1.13x AU$-2.24 Million
2011 -149.80% -1212.98% 0.08x 1.54x AU$-2.77 Million
2012 -112.08% -511.68% 0.12x 1.77x AU$-2.50 Million
2013 -2441.01% -2363.27% 0.06x 17.43x AU$-3.55 Million
2014 -36.76% -254.33% 0.13x 1.12x AU$-3.17 Million
2015 -55.96% -268.54% 0.17x 1.25x AU$-3.17 Million
2016 -143.08% -706.12% 0.11x 1.79x AU$-7.56 Million
2017 -103.49% -487.33% 0.17x 1.26x AU$-7.46 Million
2018 -35.68% -163.38% 0.20x 1.10x AU$-3.85 Million
2019 -63.34% -195.04% 0.28x 1.16x AU$-5.39 Million
2020 -51.86% -116.23% 0.41x 1.10x AU$-3.49 Million
2021 -32.38% -5751.61% 0.01x 1.04x AU$-10.97 Million
2022 -12.31% -373.01% 0.03x 1.07x AU$-5.17 Million
2023 -19.30% -209.81% 0.08x 1.12x AU$-5.75 Million
2024 -54.58% -141.49% 0.32x 1.22x AU$-8.21 Million
2025 -64.64% -71.58% 0.72x 1.26x AU$-6.02 Million

Industry Comparison

This section compares Immuron Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $31,815,679
  • Average return on equity (ROE) among peers: -60.84%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Immuron Ltd (IMC) AU$8.07 Million -20.89% 0.26x $4.76 Million
Adalta Ltd (1AD) $2.03 Million -265.03% 1.74x $171.91K
Algorae Pharmaceuticals Ltd (1AI) $2.88 Million -33.65% 0.18x $9.99 Million
ACRUX Ltd (ACR) $17.49 Million -17.99% 0.05x $2.16 Million
Argenica Therapeutics Ltd (AGN) $13.95 Million -39.28% 0.17x $11.42 Million
Arovella Therapeutics Ltd (ALA) $11.23 Million -77.89% 0.18x $39.76 Million
Anatara Lifesciences Ltd (ANR) $5.92 Million -48.49% 0.08x $718.75K
Bio-Gene Technology Ltd (BGT) $4.25 Million -56.43% 0.18x $2.33 Million
BTC Health Ltd (BTC) $11.34 Million -4.81% 0.03x $364.22
Cambium Bio Ltd (CMB) $8.27 Million -79.86% 0.16x $8.11 Million
Clinuvel Pharmaceuticals Ltd (CUV) $240.81 Million 15.02% 0.13x $251.65 Million